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Translational relevance  
AGC (protein family A, G and C) kinases are serine threonine kinases, which include 
ROCK, AKT and p70S6K. They are key anticancer targets with relevance to motility, 
metastasis, survival of cancer cells and an immune suppressive state within tumors. 
AT13148 is a potent ROCK and AKT inhibitor. The clinical tolerability profile was 
dominated by dose-limiting toxicities suggestive of ROCK inhibition (hypotension and 
headaches) and not AKT inhibition (hyperglycemia and rash).  Careful consideration is 
warranted while developing multi-kinase inhibitors involving AGC kinases as they can have 
broad activity in preclinical models, but their clinical development using systemic routes of 
administration may be limited by side effect profiles related to potent inhibition of ROCK.  
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Abstract 
Purpose  
AT13148 is an oral AGC kinase inhibitor, which potently inhibits ROCK and AKT kinases. 
In preclinical models, AT13148 has been shown to have anti-metastatic and anti-
proliferative activity.  
 
Experimental Design 
The trial followed a rolling six design during dose escalation. An intra-patient dose 
escalation arm to evaluate tolerability and a biopsy cohort to study pharmacodynamic (PD) 
effects were later added. AT13148 was administered orally three days a week (Mon-Wed-
Fri) in 28-day cycles. Pharmacokinetic profiles were assessed using mass spectrometry 
and PD studies included quantifying p-GSK3β levels in platelet-rich plasma (PRP) and p-
cofilin, p-MLC2 levels in tumor biopsies.   
 
Results  
Fifty-one patients were treated on study. The safety of 5 - 300 mg of AT13148 was 
studied. Further, the doses of 120-180-240 mg were studied in an intra-patient dose 
escalation cohort. The dose-limiting toxicities included hypotension (300 mg), pneumonitis 
and elevated liver enzymes (240 mg) and skin rash (180 mg). The most common side 
effects were fatigue, nausea, headaches and hypotension. Based on tolerability 180 mg 
was considered the maximally tolerated dose. At 180 mg, mean Cmax and AUC were 383 
nM and 13399 nM.h, respectively.  At 180 mg, ≥50% reduction of p-cofilin was observed in 
3/8 post-treatment biopsies. 
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Conclusions 
AT13148 was the first dual potent ROCK-AKT inhibitor to be investigated for the treatment 
of solid tumors. The narrow therapeutic index and the pharmacokinetic profile led to 
recommend not developing this compound further. There are significant lessons learned in 
designing and testing agents that simultaneously inhibit multiple kinases including AGC 
kinases in cancer.  
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Introduction  
Phosphoinositide 3-kinases (PI3Ks) are key mediators of intracellular signaling between 
the membrane-bound receptor tyrosine kinases (RTKs) and downstream effector 
molecules, such as AKT/PKB, m-TOR, GSK3β, S6K and S6, which control a range of vital 
cellular functions deregulated in cancer cells, including cellular growth, proliferation, and 
survival (1). There are currently multiple drugs licensed for use in the treatment of cancer 
in this pathway, ie PI3Kα, PI3Kδ and m-TOR inhibitors (2-5). 
 
AGC kinases are a group of evolutionarily-related serine threonine kinases, some of which 
are deregulated in cancer (6).  PDK1/PKA/PKB and S6K are key components of the PI3K 
pathway and have been targeted using a wide range of PI3K pathway inhibitors (1). 
However, there remain other AGC kinases such as Rho-associated coiled-coil containing 
protein kinase (ROCK) that influence growth (7-9) and metastasis of cancer cells 
independent of the PI3K pathway (10). ROCK-myosin II signaling has also recently been 
shown to be important in modulating resistance to targeted therapy in melanoma and an 
immunosuppressive environment within tumors (11).  
 
AT13148 was discovered using a high throughput x-ray crystallography and fragment-
based drug design as an AGC kinase inhibitor that inhibited AKT and other AGC kinases 
such as ROCK (12). It was hypothesized that additional AGC kinase activity would result in 
increased anti-proliferative and anti-metastatic efficacy and possibly reduce resistance to 
selective AKT inhibition (13,14). Preclinical studies have evaluated the efficacy of 
AT13148 in blocking invasion and metastasis in melanoma and pancreatic cancer models 
(14,15). In addition, AT13148 has been shown to inhibit PI3K signaling and induce cell 
death in a range of preclinical models, including gastric and prostate cancer models 
(13,16). There are currently multiple selective AKT inhibitors in late stages of clinical 
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development (17) and ROCK inhibitors are licensed for use in non-oncological indications, 
such as pulmonary hypertension (18), but have not been clinically tested in cancer patients 
until now.  Herein, we report the results from the first-in-human phase I study of AT13148, 
a potent dual AKT/ROCK inhibitor, in adults with advanced solid tumors. 
 
Material and Methods 
Design 
The study followed a rolling 6 dose escalation design (19). Following an amendment, two 
cohorts were added. The first included an intra-patient dose escalation in patients at dose 
levels 120-180-240 mg starting with one week dosing at the lowest dose followed by 
escalating to the next dose of 180 mg until the highest dose of 240 mg during cycle 1. The 
aim of this cohort was to evaluate if the on-target hypotension would be better tolerated if 
the dose was increased in a stepwise fashion. The second amendment introduced a 
mandatory biopsy cohort where fresh biopsies were collected before and after treatment at 
the recommended phase II dose (RP2D) of 180 mg. The trial was conducted to ethical 
principles laid down by the Declaration of Helsinki and the protocol was reviewed by 
regulatory agencies (MHRA, UK) and a UK national research ethics committee. Written 
informed consent was obtained (patients were given an information sheet and signed a 
consent form) prior to patients enrolling in the clinical trial.  Inclusion criteria included the 
fact that patients had received standard-of-care treatment for their metastatic solid tumors 
and had adequate renal and hepatic function (full inclusion and exclusion criteria in 
Supplementary Data). Key exclusion criteria included an abnormal fasting blood sugar and 
a history of hypertension on anti-hypertensive medication.  
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AT13148 was administered orally three days a week (Mon-Wed-Fri) in 28-day cycles. 
Patients were seen weekly for toxicity assessments and imaging to evaluate tumor 
response was conducted every 2 cycles. 
 
Pharmacokinetics 
A single dose of AT13148 was administered 7 days before cycle 1 for pharmacokinetic 
analysis.  A full pharmacokinetic profile was also carried out on cycle 2, day 1.  Blood was 
collected at baseline, 15 minutes, 30 minutes, 1, 2, 6, 12, 24, 48, 72 and 96 hours post-
dose for analysis (the last two being optional from Cohort 6, 160 mg, cycle 1). Plasma 
concentrations of AT1318 were measured by liquid chromatography mass spectrometry 
(see Supplementary Data) Pharmacokinetic parameters were derived from Phoenix 
WinNonlin using non-compartmental analysis.  
 
Pharmacodynamics 
Blood samples for pharmacodynamics were taken at baseline, 2 hrs, 6 hrs, 24 hrs and 48 
hrs after treatment on the run-in dose at day -47 to -4 and on cycle 2, day 1.  
Phosphorylation of GSK3 Ser9 (p-GSK3) was quantified in platelet-rich plasma 
(PRP) extracted from serial blood samples using electrochemiluminescent immunoassays 
on the MesoScale Discovery (MSD®) technology platform using previously validated 
techniques (20).  Relative changes in p-GSK3β were reported as a ratio, calculated as the 
percentage of baseline levels normalized to total GSK3β. Phosphorylated cofilin protein 
levels in tumor biopsies pre-dose and post-AT13148 treatment (between cycle 1, day 15 or 
cycle 2, day 1, 24 hrs post-treatment) were measured using the Protein Simple WES 
Assay platform. Changes in phospho- and total cofilin normalized to GAPDH were 
measured in the form of chemiluminescence signals with the area under the curve (AUC) 
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calculated for each analyte by the WES Compass software. Relative changes in 
phosphorylated cofilin were reported as a percentage of pre-dose protein levels. 
 
Phosphorylation of MLC2 was quantified using immunohistochemistry (IHC). Four-µm thick 
sections were incubated at 60 C for 20 min and then subjected to antigen retrieval using 
Access Super Tris pH 9 buffer (A Menarini Diagnostics) at 110 C for 6 min in a Decloaking 
Chamber NxGen (Biocare Medical). Samples were blocked with Dual Endogenous Enzyme-
Blocking Reagent (Dako) for 10 min and were then incubated with primary antibodies for 40 
min at room temperature (RT), washed and then incubated with biotinylated secondary 
antibodies (rabbit, mouse or rat; 1:200; Vector-Labs) for 30 min at RT. Signal was then 
amplified using a VECTASTAIN ABC HRP kit (PK-4000) for 20 min at RT and the reaction 
was developed using VIP substrate (SK-4600, Vector-Labs) for 10 min at RT.  Stainings were 
counterstained with hematoxylin. The slides were imaged using a NanoZoomer S210 slide 
scanner (Hamamatsu, Japan). Staining quantification was performed using QuPath 0.1.2.  In 
order to quantify p-MLC2, the images were analyzed using positive cell detection and three 
different thresholds were applied according to the intensity scores (0, 1, 2 and 3).  Next, the 
software was trained by creating a random trees classification algorithm combined with the 
intensity information in order to differentiate tumor from stroma, necrosis and immune cells 
(21).  
 
Results 
Patient characteristics 
A total of 56 patients with solid tumors who had previously received standard-of-care 
treatment were enrolled on the study from December 2012 to December 2017, of whom 51 
patients received at least one dose of AT13148. The demographics of the patients 
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included a male/female ratio of 25/31, age range of 34 - 76 yrs and the most common 
tumor types were colorectal and breast cancer (Supplementary Table 1). 
 
Safety 
Patients were initially treated across a dose rage of 5 – 300 mg a day in 8 cohorts 
following a rolling six design during the dose escalation. Two further cohorts were then 
added: first, a cohort that included intra-patient dose escalation (Cohort 9) over 3 dose 
levels (120 mg -180 mg - 240 mg) to evaluate whether incremental increase of dose over a 
period of 3 weeks could improve tolerability; then, a mandatory biopsy cohort of patients 
was treated at the RP2D of 180 mg (Cohort 10) to study pharmacodynamic effects in pre- 
and post-treatment biopsies (Figure 1). 
 
The dose escalation proceeded by dose doubling from 5 - 160 mg with no dose-limiting 
toxicities reported. At the dose of 160 mg (Cohort 6), following multiple non-dose-limiting 
toxicity (DLT) grade 3 toxicities of hypotension and diarrhea, the dose escalation 
proceeded by a 50% increase to 240 mg (Cohort 7). There was one DLT of elevated liver 
enzymes seen at 240 mg in addition to multiple episodes of grade 2 toxicities such as 
nausea, fatigue, anorexia and hypotension. As only 1 in 6 evaluable patients had a DLT, 
the dose was escalated cautiously by a further 25% to 300 mg (Cohort 8). At this dose 
level, two patients experienced grade 2 hypotension, one patient experienced grade 3 
hypotension and one patient experienced grade 4 hypotension with a systolic blood 
pressure of less than 40 mm Hg requiring inotropic support. No further patients were 
treated at the dose of 300 mg following the adverse event. In Cohort 9 (intra-patient dose 
escalation cohort), two DLTs (grade 3 pneumonitis at 240 mg and grade 3 rash at 180 mg) 
were reported. However, multiple grade 1 and 2 toxicities including grade 2 fatigue were 
seen at 240 mg and limited continuation of this approach. The dose was therefore de-
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escalated and the maximally tolerated dose was established at a dose of 180 mg AT13148 
orally given on days 1, 3 and 5 of each week.  As a composite of the flat dose escalation 
and the intra-patient dose escalation cohort, a dose of 180 mg was considered the 
maximally tolerated dose of AT13148. 
 
The most common treatment related side effects were hypotension, nausea, headache 
and fatigue (Table 1). There were four grade 3 or 4 events that were considered dose-
limiting toxicities, which included hypotension at 300 mg, elevated transaminases and 
pneumonitis at 240 mg and a maculopapular rash at 180 mg.  
 
The most common known on-target toxicity of AT13148 included hypotension. This was 
often associated with headaches and occurred within 8 hrs of dosing. Fatigue and nausea 
were commonly seen at or above the dose level 160 mg. Although one episode of 
elevated liver enzymes was described as a dose-limiting toxicity in Cohort 7 (240 mg), 
there were no dose-dependent trends of increased liver transaminases across different 
dose levels. Rash was seen in 6/51 (11.8%) of patients but was dose-limiting in only one 
patient.  
 
Pharmacokinetics 
AT13148 was measured in plasma in all patients and data was obtained from 44 patients 
across nine cohorts (flat dose Cohorts 1 - 8 and 10). Data was limited from Cohort 8 
(300 mg AT13148) as there were only three evaluable patients, and only one patient 
received a second cycle of AT13148. 
Maximum plasma concentrations in cycle 1 ranged between 7 and 964 nmol/L with mean 
values of 22 to 661 nmol/L. In cycle 2, plasma concentrations of AT13148 were between 
18 and 1097 nmo/L with mean values of 24 to 712 nmol/L. There was a dose-related 
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increase in the mean Cmax and AUC r
2 = 0.97 and 0.98, respectively (Supplementary 
Figure 1), however, a high intra-patient variability was observed at doses of 80 mg and 
above. In many instances (34 patient profiles of the 55), the terminal t½ was not accurately 
established, which also affected related PK parameters (clearance, volume of distribution 
etc.). This was addressed with additional (optional) sampling times over 48 hours (at 72 
and 96 hours). Based on 14 evaluable patients in cycle 1, the half-life of AT13148 ranged 
between 14.4 and 32.2 hours (Table 2). At the tolerable dose of 180 mg free drug levels or 
exposure were below those measured in preclinical efficacy experiments.   
 
PK-hypotension relationships 
Due to the ROCK inhibitory activity of the drug, hypotension was regarded as both an on-
target toxicity (22) and a pharmacodynamic biomarker. The maximum decrease in supine 
systolic blood pressure and Cmax or AUClast were studied. Where there was matched data 
for blood pressure and plasma drug concentrations available, there was a weak linear 
correlation seen between hypotension and both Cmax and AUC0-last (r
2 0.25 and 0.17, 
respectively) (Figure 2).  However, looking at individual cases, of the eight patients with 
the most severe hypotension (a fall of greater than 30 mm Hg) six patients had high 
exposure in terms of Cmax >350 nM and AUC0-last >1000 nM·h. The high incidence of 
hypotension found at high doses became dose-limiting to the trial and halted recruitment at 
300 mg. 
 
Pharmacodynamics 
Phosphorylation of GSK3β was quantified in platelet-rich plasma to assess AKT inhibition. 
At doses 160-300 mg there was a weak trend in the relationship between the plasma 
concentration and the p-GSK3β levels; r2 =0.17 (Figure 3A). At the non-tolerated dose 
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level of 300 mg, there was a statistically significant reduction of p-GSK3β levels in platelet-
rich plasma 2 - 6 hrs after treatment when compared to predose (Figure 3B). We also 
studied the phosphorylation of cofilin, a known downstream effector of ROCK activity in 
pre- and post-treatment biopsies at the 180 mg dose level. Of the 8 pre- and post-
treatment biopsies conducted, 5/8 showed a reduction of p-cofilin in post-treatment 
biopsies and 3/8 showed >50% reduction of p-cofilin (Figure 4A). Myosin II is regulated by 
ROCK via direct phosphorylation of the regulatory light chain (MLC2). p-MLC2 was 
assayed using immunohistochemistry in 5 paired biopsies and there was a reduction in H 
scores in post- treatment samples in 1/5 paired biopsies (Figure 4B). 
 
Clinical efficacy 
No complete or partial responses were seen in the study. The median number of cycles of 
AT13148 on the study was 2 (range 1 - 10). One patient with NSCLC (adenocarcinoma) 
was on the study for 10 cycles and had been tested and shown not to have an EGFR 
mutation or ALK rearrangement as part of their standard-of-care.   
 
Discussion 
AT13148 is an AGC kinase inhibitor with potent ROCK and AKT inhibitory activity (13). 
ROCK inhibitors have attracted interest due to their role in tumor invasion, cancer 
metastasis and stromal remodelling (23,24). In addition, there are a number of studies 
demonstrating preclinical anti-proliferative activity in melanoma (7), neuroblastoma (9), 
pancreatic cancer (15), lung cancer and leukemia (8).  AT13148, to our knowledge, is the 
first dual ROCK-AKT inhibitor that has been evaluated in a clinical trial as an anticancer 
agent.  
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Vasodilation caused by ROCK inhibition led to a high number of patients who received  
AT13148 experiencing hypotension, which was dose-limiting at a dose of 300 mg. Though 
not dose-limiting, headaches were a common toxicity seen in this study and were also 
likely to be due to vasodilatation. This property of ROCK inhibitors has led to its use in 
pulmonary hypertension (25) and in the treatment of cerebral vasospasm following 
subarachnoid hemorrhage (26). Other dose-limiting toxicities included pneumonitis and 
skin rash; these have previously been reported in agents such as PI3K, AKT or m-TOR 
inhibition (2,5,20,27-29). One dose-limiting toxicity of elevated liver enzymes was seen. 
Elevated liver enzymes have been reported in PI3K pathway inhibitors but it is not clear if 
this an on-target toxicity (30,31). Nausea and fatigue were other common toxicities, which 
were non-specific and have been reported across a wide range of other anticancer drugs. 
Interestingly, hyperglycemia and non-neutropenic infections, which are common features 
of PI3K pathway inhibitors, were not commonly seen in this study (32,33). 
 
The pharmacokinetic profile of AT13148 showed a high degree of variability when 
administered in the current formulation. This led to considerable overlap between 
exposure to AT13148 at dose levels of 160 mg and above. This was considered a 
challenge and risk for further development of the current formulation of the drug 
considering the narrow therapeutic index. 
 
Interestingly, postural hypotension was seen at dose levels above 80 mg, suggestive of 
ROCK inhibition. Therefore, we decided to study the relationship of Cmax and AUC of 
AT13148 to changes in blood pressure where matched data points were available. This 
showed a low to moderate correlation.  Pharmacodynamic analysis in platelet-rich plasma 
demonstrated a transient reduction of p-GSK3β levels at the non-tolerable dose of 300 mg; 
a trend towards reduction of levels of p-GSK3β between 160 - 300 mg.  Reduction of p-
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GSK3β has been shown to be a reproducible biomarker of AKT inhibition (20,34) and 
reduction of p-GSKRβ was demonstrated in xenograft models treated with AT13148 
showing growth delay (13).  Finally, there was a 50% reduction in phosphorylation of cofilin 
in 3/8 patients and reduction in the phosphorylation of MLC2 in only 1/5 paired biopsies 
studied with pre- and post-tumor biopsies at the dose level of 180 mg.  A reduction of p-
MLC2 has been shown to be a biomarker of ROCK inhibition in AT13148-treated mice in-
vivo. However, measurement of p-MLC2 levels in xenograft tissue that had shown tumor 
growth delay has not been performed (14,15), thus, even if a reduction of p-MLC2 was 
demonstrable in all samples, interpretation of the data would need to be put into this 
context. The phosphorylation of coflin has been shown to be a biomarker of ROCK 
inhibition (7), but specific experiments measuring p-cofilin in xenografts of AT13148-
treated mice have not been performed and thus it is difficult to interpret the findings in this 
study. However, given that changes in both the biomarkers were not seen in a majority of 
the samples treated at the RP2D of 180 mg thrice a week, these findings were not 
suggestive of consistent and robust ROCK inhibition in tumor tissue. 
 
There were no clinical responses seen in the study. The reasons for lack of single agent 
response could be many. The anticancer activity of ROCK inhibitors is predominantly 
towards causing a reduction in metastatic spread. This first-in-human study was geared 
towards defining tolerability and PK-PD relationships, and recruited patients with advanced 
solid tumors.  It would not be possible to study anti-metastatic activity of such a drug in 
these patients: the dose-limiting on-target toxicity of hypotension limited the escalation to 
biological effective levels of ROCK inhibition in tumor tissue. Further, the hypotension 
limited the ability to sufficiently inhibit other key AGC kinases such as AKT, which 
contributed to anti-proliferative activity in preclinical models. Prospective sequencing of 
tumor to enrich cohorts with patients whose tumors had PIK3CA or AKT mutations would 
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have improved the chances of observing responses but, given that there were no toxicities 
or consistent biomarker changes suggestive of AKT inhibition, this would have been 
unlikely. Future research into ROCK inhibitors could consider isoform specific ROCK II 
inhibitors that may cause reduced hypotension and the possibility of topical applications for 
selected skin cancers,  which could reduce other systemic side effects (18). 
 
The pharmacological audit trail defines multiple factors involved in go-no-go decisions in 
drug development (35). The current first-in-human study demonstrated multiple factors that 
would make further development of this agent challenging, including its toxicity seen, 
variable pharmacokinetic profile and inability to reproducibly inhibit AGC kinases in tumor 
tissue.  
 
AT13148 also brings poly-pharmacology of anticancer drugs into question. It is 
increasingly found that targeted anticancer drugs inhibit multiple targets (36,37).  
Importantly, this has led to drugs which inhibit multiple targets being licensed for 
indications which are relevant to one target and not to the other e.g. sorafenib is licensed 
in renal cancer for its VEGFR inhibitory activity and not in melanoma for its RAF inhibitory 
activity (38,39) and crezotinib has been licensed in lung cancer for its ALK inhibitory 
activity and not as an MET inhibitor (40,41). AT13148 inhibited multiple AGC kinases and 
was found to cause cell death and apoptosis when compared to more selective AKT 
inhibitors in-vitro. In a biochemical screen, AT13148 was a more potent ROCK inhibitor 
compared to an AKT inhibitor. The IC50 of AT13148 for ROCK I and ROCK 2 was 6 nM 
and 4 nM, respectively, when compared to that for AKT1, AKT2 and AKT3, 38 nM, 402 nM 
and 50 nM, respectively (13). The additional putative cytotoxic anticancer effects of ROCK 
I/II inhibitory activity of AT13148 could not be exploited due to clinical hypotension caused 
by its activity on normal tissue. The current trial raises a further important issue 
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surrounding cancer drugs that can, by virtue of inhibiting multiple kinases, target the 
cardiovascular system (eg VEGFR or vascular disrupting agents). In these instances, it 
could be hypothesized that cells of the vasculature are likely to be exposed to the drug 
earlier than cells of tumors and possibly at a higher concentration, resulting in 
cardiovascular adverse events being limiting: for example, the multikinase inhibitor, 
ilorasertib, targeted the VEGFR and Aurora kinase families resulting in the VEGR-related 
adverse events being limiting (42). In the case of AT13148 it is difficult to know if the 
cardiovascular side effects occurred at lower concentrations required for AKT inhibition 
because the drug inhibits ROCK more potently or because cells in the vascular system are 
likely to be exposed to such drugs earlier, and to a possibly higher concentration, than 
cancer cells in the tumor.    
This clinical information will be of importance to researchers developing ROCK inhibitors 
or other AGC kinases as anticancer drugs and makes the case for the development of 
specific inhibitors of individual AGC kinases. 
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Cohort 1 
5 mg 
(n=4) 
Cohort 2 
10 mg 
(n=5) 
Cohort 3 
20 mg 
(n=3) 
Cohort 4 
40 mg 
(n=3) 
Cohort 5 
80 mg 
(n=4) 
Cohort 6 
160 mg 
(n=7) 
Cohort 7 
240 mg 
(n=6) 
Cohort 8 
300 mg 
(n=5) 
Cohort 9 
120-180-240 mg 
(n=7) 
Cohort 10 
180 mg 
(n=7) 
Treatment Emergent 
Adverse Event 
Total No. 
subjects 
(n = 51) 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 4 1 2 3 1 2 3 
GASTROINTESTINAL 
DISORDERS 
                                
Diarrhea 7 (13.7% )                  1 1       2   3   
Nausea 15 (29.4% ) 1               3   1 1  2    4   3   
Vomiting 7 (13.7% )                1   3   1    1   1   
GENERAL 
DISORDERS AND 
ADMINISTRATION 
SITE CONDITIONS 
                                
Fatigue 9 (17.6% )  1                 1 1      2 2  2   
METABOLISM AND 
NUTRITION 
DISORDERS 
                                
Anorexia 7 (13.7% ) 1                1   2      2   1   
NERVOUS SYSTEM 
DISORDERS 
                                
Headache 12 (23.5% )                1 2  2   3       4   
VASCULAR 
DISORDERS 
                                
Flushing 6 (11.8% )                 1  2 1  1       1   
Hypotension 20 (39.2% )    1            3 1 1 3 1   3 1 1 2   1  2 
 
Table 1. 
Treatment emergent adverse events  
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Cycle 1 
Tmax  
(h) 
Cmax 
(nmol/L) 
HL Lambda z 
(h) 
AUClast 
(h*nmol/L) 
* AUC to 48 h 
(h*nmol/L) 
AUCINF obs 
(h*nmol/L) 
Vz F obs 
(L) 
Cl F obs 
(L/h) 
Cohort 1 
5mg 
Mean 5 20 60 400 400 900 1400 20 
SD 5 15 27 21 210 350 290 11 
% CV 97 70.0 41 54 54 40 21 60 
Cohort 2 
10mg 
Mean 6 15 40 300 300 600 1900 100 
SD 4.2 4.8 30 190 190 460 670 95 
% CV 75 32 85.0 66 66 77 36 96 
Cohort 3 
20mg 
Mean 4 30 20 600 600 1000 2000 90 
SD 2.8 16 13 440 440 750 660 72 
% CV 66 46 56 70 70 78 32 83 
Cohort 4 
40mg 
Mean 1.99 120 15 1900 1900 2100 1100 50 
SD 0.03 21 1.00 540 540 630 310 17 
% CV 2 18 7 29 29 30 28 33 
Cohort 5 
80mg 
Mean 3 180 50 5000 5000 10000 1600 30 
SD 2 69 44 3000 3000 16000 910 22 
% CV 67 38 82 61 61 118 57 67 
Cohort 6 
160mg 
Mean 5 400 40 12000 10000 20000 2000 40 
SD 2 290 22 7900 5900 16000 1300 28 
% CV 41 66 52 64 57 79 72 75 
Cohort 7 
240mg 
Mean 5 500 40 15000 13000 30000 2000 50 
SD 2 280 17 9000 9000 24000 930 36 
% CV 40.0 61 44 63 70 94 48 80 
Cohort 8 
300mg 
Mean 6.1 700 60 20000 20000 40000 1400 18 
SD 0.12 130 35 4100 4100 10000 600 4.8 
% CV 2 20 57 21 21 23 42 26 
Cohort 10 
180mg 
Mean 4 400 40 13000 9000 20000 2000 50 
SD 2.3 190 21 8000 4700 14000 2200 59 
% CV 64 50 51 60 52 74 94 110 
 
Table 2. 
Pharmacokinetic parameters of AT13148 
The pharmacokinetic parameters between 5 - 300 mg in cycle 1. There was considerable variation of AUC and Cmax at doses of 160 
mg and above.  
Research. 
on July 8, 2020. © 2020 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 2, 2020; DOI: 10.1158/1078-0432.CCR-20-0700 
27 
 
LEGENDS TO FIGURES 
 
Figure 1 
The dose escalation scheme 
Dose was doubled from 5 - 160 mg, following which a more conservative increase in 
dose to 240 mg and 300 mg was evaluated. Following grade 4 hypotension being seen at 
300 mg an intra-patient dose escalation schedule was explored to evaluate if this 
improved tolerability of higher doses. The dose of 180 mg was considered tolerated pre- 
and post- treatment biopsies were conducted to evaluate pharmacodynamics effects. 
 
Figure 2 
Relationship of hypotension and pharmacokinetic parameters 
The maximum drop in supine systolic blood pressure was measured and correlated with 
PK profiles of individual patients in patients where matched blood pressure and PK 
measurements were available at doses 160 mg, 240 mg and 300 mg. A) Relationship 
between AUC and drop in blood pressure r2 = 0.17. B) Relationship between Cmax and 
maximal drop in blood pressure r2 = 0.25. 
 
Figure 3 
Pharmacodynamic effects in platelet-rich plasma 
Phosphorylation of GSK3β is a downstream event of AKT activation and reduction of p-
GSK3β was quantified in platelet rich plasma before and after treatment with AT13148.  
A) The relationship of the plasma levels of AT13148 and p-GSK3β across the dose levels 
Research. 
on July 8, 2020. © 2020 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 2, 2020; DOI: 10.1158/1078-0432.CCR-20-0700 
28 
 
of 160 - 300 mg. There was a trend towards reduction of p-GSK3β and increasing 
plasma levels of AT13148, r2 = 0.17, p = 0.0354.  B) p-GSK3β normalized to total GSK3β 
levels were reduced between 2 - 24 hrs after treatment of AT3148 at the 300 mg cohort. 
The asterisk indicates significance in Dunnett’s test.  The changes were not significant at 
doses lower than 300 mg.  
 
Figure 4 
Pharmacodynamic effects in tumor tissue 
Biopsies were done at the dose level of 180 mg thrice a week. Phosphorylation of cofilin 
normalized to GAPDH at baseline and at 15 - 28 days of intermittent dosing was assayed 
using an immuno-chemiluminescence assays and results are presented as percentage of 
pre-dose levels (A) A reduction of more than 50% of p-cofilin levels were seen in 3/8 
patients. (B) Phosphorylation of MLC2 was measured by IHC in pre- and post-treatment 
tumor specimens of patients treated with AT13148 showing reduction in phosphorylation 
in only 1/5 samples. 
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